Engage Bio has developed an innovative platform known as Tethosomes, which represents a new class of non-viral DNA delivery systems. This technology addresses significant challenges in the field of genetic medicine, particularly in terms of potency and toxicity. Tethosomes utilize proven lipid nanoparticle (LNP) technology to deliver therapeutic DNA and mRNA that encodes a proprietary Tethosome protein. This protein enhances the localization of DNA to the nucleus, resulting in over 100-fold increased expression. Additionally, the Tethosome platform is designed to be non-immunogenic, meaning it can evade immune detection, allowing for safe and effective re-dosing and prolonged expression from a single administration.

The scalability of the Tethosome platform is another key advantage, as it features low manufacturing complexity, making it suitable for widespread application in various therapeutic areas. Engage Bio is actively seeking partnerships to expand the use of its Tethosome technology in gene replacement therapies, oncology, and durable therapeutic protein expression. The company is committed to advancing genetic medicine with the goal of improving human health, leveraging its innovative platform to develop new treatments that can address complex diseases.

United States

Engage Bio is unleashing the potential of DNA medicines to eliminate disease. Our platform represents a new class of non-viral DNA medicines that are highly potent, non-immunogenic, durable, and ready to scale.

Engage Bio

Company Details